Kornimate/medical-research-clean huggingface dataset:
exploratory study to evaluate the use of the rxsight light adjustable lens (lal) and the light delivery device (ldd) to improve visual outcomes

Conditions: Aphakia; Cataract

Summary: the objective of this study is to evaluate, for the visual correction of aphakia, whether the rxsight light adjustable lens (lal) and light delivery device (ldd) can be used to improve visual outcomes after performing adjustments of the lal with the ldd. this is an exploratory study. no primary effectiveness endpoints will be identified.


Eligibility criteria:
inclusion criteria: * must sign a written informed consent form and be willing to undergo cataract surgery for unilateral or bilateral implantation of the rxlal. * between the ages of 40 and 80 inclusive on the day the cataract surgery is performed. * study eye must have cataract causing reduction in best corrected distance visual acuity (bcdva) to a level of 20/32 or worse with or without a glare source. * willing and able to comply with the requirements for study specific procedures and visits. exclusion criteria: * study eye with pseudoexfoliation. * study eye with diabetes with any evidence of retinopathy. * study eye with evidence of glaucomatous optic neuropathy. * study eye with history of uveitis. * study eye with prior history of intacs, radial keratotomy (rk), conductive keratoplasty (ck), astigmatic keratotomy (ak), phakic implantable collamer lens (icl), corneal inlay, or with previous pterygium excision unless the pterygium did not extend more than 2mm onto the cornea from the limbus. * subjects taking systemic medication that may increase sensitivity to uv light. * subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen. * study eye with history of ocular herpes simplex virus. * study eye with history of a congenital color vision defect

Keywords: light adjustable lens intraocular lens lal
improving household air quality in homes with children

Conditions: Lung Diseases; Asthma

Summary: the purpose of this study is to determine if real-time feedback (lights/sounds) from small smoke particle monitors and brief coaching will encourage parents to reduce young children's secondhand tobacco smoke exposure in their home.

the purpose of this efficacy study is to test whether children's home secondhand tobacco smoke exposure (measured by cotinine \& nicotine assays, fine particulates and reports of smoking in the home and/or home smoking bans) can be reduced by using custom particle monitors to provide real-time feedback to household residents plus brief advice/praise.

Eligibility criteria:
inclusion criteria: * families with at least one parent or guardian (18 years of age or older), * household resident who smokes tobacco, * child under fourteen years old exposed to tobacco smoking in the home * plans to live in san diego county for at least three months.

Keywords: secondhand smoke
giant cell tumor of the extremities treated with surgery and/or medical treatment

Conditions: Giant Cell Tumor of Bone

Summary: the purpose of this project is to present the outcomes of patients with giant cell tumor of bone (gctb) who were treated with surgery and/or medical treatment in a single institution.

the investigators retrospectively review patients treated for gctb of the extremities between 1990 and 2013 in a single institution. we evaluate the recurrence free survival rate after surgical and medical treatment of patients with gctb of the extremities to determine the influence of the surgical approach, denosumab therapy, local tumor presentation, and demographic factors on the risk of recurrence.

Eligibility criteria:
inclusion criteria: * giant cell tumors of the extremities exclusion criteria: * giant cell tumors of the spine and pelvis

Keywords: bone tumors giant cell tumor treatment
a clinical trial of ginseng in diabetes

Conditions: Diabetes

Summary: a clinical study of ginseng its potential affect on diabetes

comparing three groups (those with \& without normal blood sugar levels) to see if there is any clinically significant change in blood sugar levels in relationship to those taking: 1. ginseng 2. ginsenoside re (a type of metabolized ginseng) 3. placebo

Eligibility criteria:
inclusion criteria: * ages 18-65 * healthy, non-diabetic * healthy, impaired glucose tolerance/mild diabetes (no medications required) exclusion criteria: * impaired glucose tolerance (borderline diabetes that requires medications) * diabetes (requiring medications) * caffeine sensitivity * known cardiac, peripheral vascular diseases * arrhythmias (irregular heart rhythms)

Keywords: health supplements ginseng diabetes
home-based exercise program with smart rehabilitation system

Conditions: Stroke

Summary: a lot of patients suffer the balance and gait disorders after stroke. many rehabilitation therapies have been provided to improve the balance and gait function in stroke patients. however, most rehabilitation therapies are performed in only hospitals, in spite of the difficulty of moving from home to hospitals for stroke patients. home-based smart rehabilitation system (uincare®, d-gate co.) can provide the specific rehabilitation training program to stroke patients in their home. this study aims to investigate the effects of the home-based exercise program with smart rehabilitation system on balance and gait functions in stroke patients.

the total 100 patients with stroke will be divided into each the intervention group and the control group. the intervention group will be provided the home-based smart rehabilitation system for 4 weeks, and the control group will be educated the conventional home rehabilitation exercise at once. the immediate effects of the home-based smart rehabilitation system on the balance and gait function will be assessed at 4 weeks after exercise and the long-term carry-over effects will be also assesed at 4 weeks after cessation of exercise.

Eligibility criteria:
inclusion criteria: * adult stroke patients (more than 18 years old) * less than 6 months after stroke onset * discharged to home or the plan to discharge to home less than 3 days * independent ambulatory function on even level (4 or more than 4 in functional ambulatory category) exclusion criteria: * advanced liver, kidney, cardiac, or pulmonary disease * a terminal medical diagnosis consistent with survival \< 1 year) * pre-existing and active major neurological disease * pre-existing and active major psychiatric disease * severe language disorders * severe cognitive disorders (10 or less than 10 in k-mmse)
effect of anodal transcranial direct current stimulation on postdural puncture headache

Conditions: Postdural Puncture Headache; Lumbar Puncture

Summary: post-dural puncture headache (pdph) is the most prevalent complication in patients undergoing diagnostic or therapeutic lumbar puncture (lp). the pathophysiology of pdph is primarily attributed to the mechanical traction on pain-sensitive intracranial nerves (e.g., the upper cervical, 5th, 9th, and 10th cranial nerves) and vascular structures, mediated by persistent dural damage leading to cerebrospinal fluid (csf) leakage and subsequent csf pressure reduction. according to the international classification of headache disorders 3rd edition (ichd3), pdph is classified as a headache subtype due to low csf pressure. it typically manifests as an orthostatic headache within a few days post-lp, accompanied by symptoms such as neck pain, tinnitus, auditory changes, photophobia, and nausea. while pdph usually resolves within 7-10 days, it can result in extended hospital stays and increased need for medication. the use of atraumatic needles is the most effective preventive measure for pdph, though other commonly recommended practices such as bed rest, fluid administration, and caffeine have questionable efficacy. transcranial direct current stimulation (tdcs) is a non-invasive brain stimulation (nibs) technique that applies low-voltage electrical currents through surface electrodes on the scalp. depending on the stimulation type-anodal or cathodal-tdcs can induce long-lasting increases or decreases in neuronal excitability and vascular-neuronal activity coupling. research has shown that anodal tdcs (a-tdcs) applied to the primary motor cortex (m1) can alleviate various pain conditions, including fibromyalgia, neuropathic pain, and headaches. the pain-relieving effects of m1 a-tdcs are believed to follow the modulation of intracortical inhibitory gabaergic transmission, and the descending connections from m1 to the thalamus and periaqueductal gray. although short-term a-tdcs treatment has shown promise in preventing migraines and medication-overuse headaches, its role in preventing and treating pdph remains unexplored. this study aims to evaluate the efficacy of preventive and therapeutic a-tdcs applied to m1 in patients undergoing diagnostic lp.


Eligibility criteria:
inclusion criteria: * age between 18 and 75 years; * indication to undergo diagnostic lumbar puncture lp. exclusion criteria: * any prior exposure to brain stimulation; * contraindications to tdcs; * a previous diagnosis of migraine or chronic headache; * usage of preventive medication at the baseline assessment; * history of depression * obesity * multiple lumbar puncture lp attempts. * cognitive impairment

Keywords: headache post-dural puncture headache transcranial direct current stimulation noninvasive brain stimulation neuromodulation
individual versus standard follicle stimulating hormone dose for controlled ovarian stimulation and insemination

Conditions: Infertility

Summary: the purpose of this study is to test if recombinant follicle stimulating hormone (rfsh) given in individual doses, according to a nomogram we have constructed based on our results from a previous study, results in more patients maturing 2-3 follicles compared to standard dose.


Eligibility criteria:
inclusion criteria: * age between 25-39 years * first stimulation with rfsh only * indication for intrauterine insemination with standard rfsh starting dose * regular menstrual bleeding with a cycle between 21-35 days * two ovaries * bilateral tuba patency * semen analysis must be sufficient for insemination according to the diagnostic analysis. exclusion criteria: * more than three former stimulated intrauterine insemination cycles
a low glycemic index diet as prevention of the catch-up fat phenomenon

Conditions: Dietary Intervention

Summary: the catch-up fat phenomenon is an evolutionary conserved physiological response to a starvationrefeeding cycle. it is characterized by long-term suppression of thermogenesis, reduced body protein regain and an increase in fat mass above basal level during refeeding. clinically, it characterises weight cycling in overweight patients which is associated with increasing fat mass (visceral fat) and increased morbidity (e.g. insulin resistance, inflammation). in this project, the physiological, cellular and molecular mechanisms of this phenomenon will be investigated in humans, mice and c. elegans. it is hypothesized that refeeding a low gi (=glycemic index)- diet after weight loss prevents the catchup fat phenomenon and its sequelae. this translational research will provide comprehensive insights into the catch-up fat phenomenon as well as provide a suitable strategy of its prevention.

in a human intervention study, changes in physiological, metabolic, and neuroendocrine functions in response to weight cycling will be investigated under controlled conditions in normal weight subjects. the mechanisms of the catch-up fat phenomenon are analysed starting from stable energy balance followed by overfeeding, weight loss and weight regain following weight loss (refeeding). changes in body composition (including ectopic fat), metabolism (resting energy expenditure, substrate oxidation rates, insulin resistance) and plasma hormone concentrations will be assessed. fat tissue probes will be used to characterise key enzymes and signalling pathways, redox status and whole genome expression. modulation of the hormonal response to weight cycling is brought about by varying macronutrient content and glycemic index of the diets. we hypothesize that, insulin and leptin resistance are explained by increased insulin secretion during the refeeding period. both, adaptive thermogenesis as well as insulin and leptin resistance can be ameliorated by attenuation of the increase in insulin and leptin secretion during refeeding a low gi diet after weight loss.

Eligibility criteria:
inclusion criteria: * normal weight (bmi 20-24 kg/m2), normal fat mass exclusion criteria: * smoking, chronic diseases, drug intake, nutrient allergies, lactose intolerance, pacemaker, metalliferous implants

Keywords: partitioning of weight gain refeeding catch-up fat phenomenon glycemic index
reduce lap-hf randomized trial i

Conditions: Heart Failure

Summary: a study to evaluate the corvia medical, inc. iasd® system ii to reduce elevated left atrial pressure in patients with heart failure.

the primary objective of this randomized controlled clinical study is to evaluate the peri-procedural safety and potential effectiveness (mechanistic effect) of implanting the iasd system ii in heart failure patients with an lv ejection fraction \>40%, elevated left sided filling pressures, and who remain symptomatic despite optimal guideline directed medical therapy (gdmt). clinical outcomes will also be evaluated.

Eligibility criteria:
key inclusion criteria: * chronic symptomatic heart failure * ongoing stable gdmt hf management and management of potential comorbidities * age ≥ 40 years old * lv ejection fraction ≥ 40% within the past 3 months, without previously documented ejection fraction \<30%. * elevated left atrial pressure with a gradient compared to right atrial pressure (rap) documented by end-expiratory pcwp during supine ergometer exercise ≥ 25mm hg, and greater than rap by ≥ 5 mm hg key exclusion criteria: * mi and/or percutaneous cardiac intervention within past 3 months; cabg in past 3 months, or current indication for coronary revascularization * cardiac resynchronization therapy initiated within the past 6 months * severe heart failure * inability to perform 6 minute walk test (distance \ 600m * history of stroke, transient ischemic attack (tia), deep vein thrombosis (dvt), or pulmonary emboli within the past 6 months * presence of significant valve disease * known clinically significant untreated carotid artery stenosis * currently requiring dialysis; or estimated-gfr \<25ml/min/1.73 m2 by ckd-epi equation
chronotherapy of 5-aminosalicylic acid in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the hypothesis of this study is that appropriate time of day of administration of oral, once daily 5-asa therapy in alignment with the host circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-asa levels. all subjects will be randomized to once daily 5-asa medications at two different times of the day: between 06:00 - 10:00 h or 18:00 - 22:00 h. three disease assessments will performed at: 1) enrollment just before randomization; 2) month 3, at the completion of first arm (condition 1), and 3) month 6, after completion of the second arm (condition 2). during these study time points, participants will be asked to complete questionnaires, track their 5-asa medication usage, provide a stool sample, blood draw, urine test, collect saliva, wear a watch to measure sleep patterns, and complete a flexible sigmoidoscopy.


Eligibility criteria:
inclusion criteria: study will include individuals that are; 1. m/f, 18-65 years of age 2. ulcerative colitis with inactive disease (mayo score ≤ 2; partial mayo score ≤ 1 with endoscopic score 0-1) 3. subclinical inflammation stool calprotectin \> 50 or crp \> mg/l above the upper limit of normal or promis fatigue score ≥ 50) 4. stable medications with no disease flares for the \> 3 months, exclusion criteria: study will not include individuals that are; 1. active uc at enrollment (mayo \> 2 and/or sigmoidoscopy score of 2 or 3) 2. regular use of suppositories or enemas within the last 3 months ora: 20052807-irb01 date irb approved: 11/6/2023 amendment date: 4/7/2024 protocol version date: 4/4/2024 7 3. use of biologics or immunomodulatory medications ( i.e. infliximab, adalimumab, azathioprine, vedolizumab, methotrexate, etc.) 4. prior ostomy or subtotal colectomy 5. recent prednisone or antibiotic use in last 12 weeks 6. major depression identified as beck depression inventory (score ≥21) 7. restless leg syndrome (score ≥ 15 on the irls study group rating scale) 8. sleep apnea (score high risk ≥ 2 or more categories on the berlin questionnaire) 9. clinically significant diabetes (hgb-a1c\>7) 10. regular use of medications that affect intestinal permeability, intestinal motility and/or nsaids 4 weeks prior to the study 11. clinically significant cardiac, renal (creatinine \> twice normal) or liver disease 12. alcohol use disorder (audit\>8) 13. chronic use of illicit drugs 14. shift work 15. inability to sign an informed consen
knowledge, attitude and practice of a group of egyptian dental interns toward caries risk assessment

Conditions: Dental Caries

Summary: scientific background(statement of the problem): dental caries is a disease that occurs through complex interaction of four major factors: the host, acidogenic bacteria, fermentable carbohydrates and time. there are many factors which contribute to dental caries incidence but do not seen in clinical examination. those things are considered as dental caries risk factors, such as socioeconomic, attitudes, knowledge and behavior toward oral health. these risk factors play an important role in incidence of the disease, significantly associated with disease progression . the traditional "drill and fill "concept has served to restore function and esthetics but it has failed to prevent development of new carious lesions. in recent years; better understanding of nature of carious process has changed this operative treatment concept to non destructive risk -based caries management. caries risk assessment is a procedure used to predict dental caries development before clinical onset of disease, through assessing risk factors contributing to progress of dental caries and let oral health care professionals to be more active in identifying and referring high risk patients for proper treatment and required prevention. rationale for carrying out this study : many studies have measured dentists' knowledge toward caries risk assessment all over the world, but no studies have examined egyptian dentists' subjective ratings of the importance of specific caries risk factors or tested whether they use this information in treatment planning. so the aim of this study to assess knowledge, attitude and practice toward caries risk assessment and management among group of dental interns in egypt. benefits to the dental interns: * challenge the knowledge of the intern dentists regarding caries risk assessment. * encourage the concept of minimally invasive dentistry to be applied in clinical practice. * accurate caries risk assessment in patients can guide clinician to give attention of their resources to high risk patients. benefits to the patients: * will benefit from proper knowledge, attitude and practice of dentists, thus proper treatment will be provided. * behavioral modification of patients toward oral hygiene practices. * reducing patient risk of developing advanced disease and may even arrest disease process. benefits to the community: -imparting knowledge of caries risk assessment to dentists will benefit their patients especially high-caries risk patients by giving proper preventive interventions that help to reduce the expected elevated incidence and severity of caries in the future, therefore the whole community will benefit.


Eligibility criteria:
inclusion criteria: 1. egyptian dental interns who completed their pediatric dentistry round in pediatric dentistry and public health department ,faculty of dentistry , cairo university. 2. intern dentists irrespective of age and sex. exclusion criteria: 1. undergraduate dental students. 2. post graduate dentists. 3. dental interns who refused to participate in the study.
a research study looking into levels of the medicine nnc0385-0434 in the body and how well it is tolerated in participants with impaired kidney function compared to participants with normal kidney function

Conditions: Chronic Kidney Disease

Summary: novo nordisk is developing a new medicine, nnc0385-0434, to help people lower their cholesterol level. the aim of this study is to look at how nnc0385-0434 works in the body and how it is removed from the body in people with impaired kidney function. all participants will receive the same dose (100 mg) of the study medicine nnc0385-0434, which will be given for 10 days in a row. participants will get the study medicine in a tablet taken orally once-daily. the study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day. the study will last for about 9-14 weeks. participants will have 15 visits to the study centre, including 2 in-house stays of 3 days and 2 nights and 13 ambulatory visits. participants' vital signs (heart rate, blood pressure, body temperature) will be measured, participants will have blood draws, urine will be collected and electrocardiograms (ecgs) will be recorded. participants cannot take part in the study if they have gastrointestinal disorders or unusual meal habits and special dietary requirements. women can only take part in the study if they cannot get pregnant.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 20.0 and 34.9 kg/m\^2 (both inclusive). * meeting the pre-defined estimated glomerular filtration rate (egfr) values based on the chronic kidney disease epidemiology collaboration (ckd-epi) equation according to kdigo 2012: group description egfr (ml/min) 1. normal renal function more than or equal to 90 2. mildly decreased renal function 60 - less than 90 3. moderately decreased renal function 30 - less than 60 4. severely decreased renal function less than 30 not requiring dialysis exclusion criteria: * presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the study doctor. * unusual meal habits and special dietary requirements or unwillingness to eat the food provided in the study.